true FY 2024 0001527352 0001527352 2024-01-01 2024-12-31 0001527352 2024-06-30 0001527352 2025-09-22 0001527352 2024-12-31 0001527352 2023-12-31 0001527352 2023-01-01 2023-12-31 0001527352 us-gaap:CommonStockMember 2022-12-31 0001527352 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001527352 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001527352 us-gaap:RetainedEarningsMember 2022-12-31 0001527352 2022-12-31 0001527352 us-gaap:CommonStockMember 2023-12-31 0001527352 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001527352 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001527352 us-gaap:RetainedEarningsMember 2023-12-31 0001527352 us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001527352 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-12-31 0001527352 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-12-31 0001527352 us-gaap:RetainedEarningsMember 2023-01-01 2023-12-31 0001527352 us-gaap:CommonStockMember 2024-01-01 2024-12-31 0001527352 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-12-31 0001527352 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-12-31 0001527352 us-gaap:RetainedEarningsMember 2024-01-01 2024-12-31 0001527352 us-gaap:CommonStockMember 2024-12-31 0001527352 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0001527352 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001527352 us-gaap:RetainedEarningsMember 2024-12-31 0001527352 us-gaap:IPOMember 2022-09-01 2022-09-20 0001527352 us-gaap:CommonStockMember 2022-09-01 2022-09-20 0001527352 us-gaap:WarrantMember 2022-09-01 2022-09-20 0001527352 2022-09-20 0001527352 2022-09-01 2022-09-20 0001527352 NXL:UnderwritersMember us-gaap:WarrantMember 2022-09-01 2022-09-20 0001527352 2023-09-30 0001527352 NXL:WiderComeLimitedMember 2023-09-30 0001527352 us-gaap:CommonStockMember 2024-06-28 2024-07-03 0001527352 NXL:DeviceSalesMember 2024-01-01 2024-12-31 0001527352 NXL:DeviceSalesMember 2023-01-01 2023-12-31 0001527352 NXL:LicensingFeeMember 2024-01-01 2024-12-31 0001527352 NXL:LicensingFeeMember 2023-01-01 2023-12-31 0001527352 us-gaap:EquipmentMember 2024-01-01 2024-12-31 0001527352 us-gaap:EquipmentMember 2023-01-01 2023-12-31 0001527352 NXL:OtherMember 2024-01-01 2024-12-31 0001527352 NXL:OtherMember 2023-01-01 2023-12-31 0001527352 country:US 2024-01-01 2024-12-31 0001527352 country:US 2023-01-01 2023-12-31 0001527352 country:CN 2024-01-01 2024-12-31 0001527352 country:CN 2023-01-01 2023-12-31 0001527352 us-gaap:PatentsMember 2024-12-31 0001527352 us-gaap:TrademarksMember 2024-12-31 0001527352 us-gaap:PatentsMember 2023-12-31 0001527352 us-gaap:TrademarksMember 2023-12-31 0001527352 us-gaap:ShortTermInvestmentsMember 2024-12-31 0001527352 us-gaap:ShortTermInvestmentsMember 2024-01-01 2024-12-31 0001527352 us-gaap:ShortTermInvestmentsMember 2023-12-31 0001527352 us-gaap:ShortTermInvestmentsMember 2023-01-01 2023-12-31 0001527352 NXL:U.S.TreasuryNotesMember 2024-12-31 0001527352 NXL:U.S.TreasuryNotesMember us-gaap:FairValueInputsLevel1Member 2024-12-31 0001527352 NXL:U.S.TreasuryNotesMember us-gaap:FairValueInputsLevel2Member 2024-12-31 0001527352 NXL:U.S.TreasuryNotesMember us-gaap:FairValueInputsLevel3Member 2024-12-31 0001527352 NXL:MutualFundsMember 2024-12-31 0001527352 NXL:MutualFundsMember us-gaap:FairValueInputsLevel1Member 2024-12-31 0001527352 NXL:MutualFundsMember us-gaap:FairValueInputsLevel2Member 2024-12-31 0001527352 NXL:MutualFundsMember us-gaap:FairValueInputsLevel3Member 2024-12-31 0001527352 us-gaap:FairValueInputsLevel1Member 2024-12-31 0001527352 us-gaap:FairValueInputsLevel2Member 2024-12-31 0001527352 us-gaap:FairValueInputsLevel3Member 2024-12-31 0001527352 us-gaap:FairValueInputsLevel1Member 2023-12-31 0001527352 us-gaap:FairValueInputsLevel2Member 2023-12-31 0001527352 us-gaap:FairValueInputsLevel3Member 2023-12-31 0001527352 us-gaap:WarrantMember 2024-01-01 2024-12-31 0001527352 us-gaap:WarrantMember 2023-01-01 2023-12-31 0001527352 us-gaap:OptionMember 2024-01-01 2024-12-31 0001527352 us-gaap:OptionMember 2023-01-01 2023-12-31 0001527352 NXL:JointVentureMember 2024-12-31 0001527352 NXL:JointVentureMember 2023-12-31 0001527352 NXL:USAsianConsultingGroupLLCMember 2018-05-01 2018-05-09 0001527352 NXL:USAsianConsultingGroupLLCMember NXL:AmendedAgreementMember 2018-05-01 2018-05-09 0001527352 NXL:USAsianConsultingGroupLLCMember 2024-01-01 2024-12-31 0001527352 NXL:USAsianConsultingGroupLLCMember 2023-01-01 2023-12-31 0001527352 NXL:USAsianConsultingGroupLLCMember NXL:LeonardOsserMember 2024-01-01 2024-12-31 0001527352 NXL:USAsianConsultingGroupLLCMember NXL:LeonardOsserMember 2023-01-01 2023-12-31 0001527352 NXL:Mr.WhiteMember 2023-06-28 2023-07-02 0001527352 NXL:Dr.OwensMember 2023-06-28 2023-07-02 0001527352 NXL:Mr.NketiahMember 2023-06-28 2023-07-02 0001527352 NXL:Ms.SheltonMember 2023-06-28 2023-07-02 0001527352 NXL:Plan2023Member 2023-06-28 2023-07-02 0001527352 NXL:LegacyVenturesInternationalIncMember 2017-12-11 0001527352 NXL:LegacyVenturesInternationalIncMember 2017-12-01 2017-12-11 0001527352 NXL:LegacyVenturesInternationalIncMember 2023-01-01 2023-12-31 0001527352 NXL:LegacyVenturesInternationalIncMember 2023-12-31 0001527352 NXL:AffiliatesOfWiderMember NXL:CollaborativeAgreementMember 2024-01-01 2024-12-31 0001527352 NXL:WiderMember 2024-01-01 2024-12-31 0001527352 NXL:InvestorsMember 2024-01-01 2024-12-31 0001527352 NXL:OutsideConsultantsMember 2024-01-01 2024-12-31 0001527352 us-gaap:RelatedPartyMember 2024-01-01 2024-12-31 0001527352 NXL:EmployeesMember 2024-01-01 2024-12-31 0001527352 NXL:CurrentAndFormerMembersOfBoardOfDirectorsMember 2024-01-01 2024-12-31 0001527352 NXL:WiderComeLimitedMember 2023-01-01 2023-12-31 0001527352 NXL:WiderComeLimitedMember 2024-01-01 2024-12-31 0001527352 NXL:VariousConsultantsMember 2023-01-01 2023-12-12 0001527352 us-gaap:StockOptionMember 2023-12-31 0001527352 us-gaap:StockOptionMember 2023-01-01 2023-12-31 0001527352 us-gaap:StockOptionMember 2024-01-01 2024-12-31 0001527352 us-gaap:StockOptionMember 2024-12-31 0001527352 NXL:Range01Member 2024-12-31 0001527352 NXL:Range01Member 2024-01-01 2024-12-31 0001527352 NXL:Range02Member 2024-12-31 0001527352 NXL:Range02Member 2024-01-01 2024-12-31 0001527352 NXL:Range03Member 2024-12-31 0001527352 NXL:Range03Member 2024-01-01 2024-12-31 0001527352 NXL:Range04Member 2024-12-31 0001527352 NXL:Range04Member 2024-01-01 2024-12-31 0001527352 srt:MinimumMember 2024-01-01 2024-12-31 0001527352 srt:MaximumMember 2024-01-01 2024-12-31 0001527352 NXL:Range1Member 2024-12-31 0001527352 NXL:Range1Member 2024-01-01 2024-12-31 0001527352 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember NXL:TwoCustomerMember 2024-01-01 2024-12-31 0001527352 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember NXL:ThreeCustomerMember 2023-01-01 2023-12-31 0001527352 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember NXL:ThreeCustomerMember 2024-01-01 2024-12-31 0001527352 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember NXL:FiveCustomerMember 2023-01-01 2023-12-31 0001527352 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember NXL:CustomerAMember 2024-01-01 2024-12-31 0001527352 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember NXL:CustomerBMember 2024-01-01 2024-12-31 0001527352 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember NXL:CustomerAMember 2023-01-01 2023-12-31 0001527352 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember NXL:CustomerBMember 2023-01-01 2023-12-31 0001527352 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember NXL:CustomerCMember 2023-01-01 2023-12-31 0001527352 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember NXL:CustomerAMember 2024-01-01 2024-12-31 0001527352 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember NXL:CustomerBRelatedPartyMember 2024-01-01 2024-12-31 0001527352 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember NXL:CustomerCMember 2024-01-01 2024-12-31 0001527352 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember NXL:CustomerARelatedPartyMember 2023-01-01 2023-12-31 0001527352 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember NXL:CustomerBMember 2023-01-01 2023-12-31 0001527352 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember NXL:CustomerCMember 2023-01-01 2023-12-31 0001527352 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember NXL:CustomerDMember 2023-01-01 2023-12-31 0001527352 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember NXL:CustomerEMember 2023-01-01 2023-12-31 0001527352 NXL:ClinicalTrialsMember 2024-01-01 2024-12-31 0001527352 NXL:ClinicalTrialsMember 2023-01-01 2023-12-31 0001527352 NXL:HALODesignMember 2024-01-01 2024-12-31 0001527352 NXL:HALODesignMember 2023-01-01 2023-12-31 0001527352 NXL:SYNCProjectMember 2024-01-01 2024-12-31 0001527352 NXL:SYNCProjectMember 2023-01-01 2023-12-31 0001527352 NXL:OtherResearchAndDevelopmentMember 2024-01-01 2024-12-31 0001527352 NXL:OtherResearchAndDevelopmentMember 2023-01-01 2023-12-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON D.C. 20549

FORM 10-K/A

Amendment No. 2

☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2024

OR

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _______ to _______.

Commission file number: 001-41507

NEXALIN TECHNOLOGY, INC.

(Exact name of Registrant as specified in its charter)

Delaware |  | 27-5566468
(State or other jurisdiction of incorporation or organization) |  | (I.R.S. Employer Identification No.)
1776 Yorktown, Suite 550 Houston, TX |  | 77056
(Address of principal executive offices) |  | (Zip Code)

Registrant’s telephone number, including area code: (832) 260-0222

Securities registered pursuant to Section 12(b) of the Act:

Title of each class |  | Trading Symbol(s) |  | Name of each exchange on which registered
Common stock, par value $0.001 per share |  | NXL |  | The Nasdaq Capital Market

Securities registered pursuant to Section 12(g) of the Securities Exchange Act: NONE

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15 (d) of the Securities Exchange Act. Yes ☐ No ☒

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer | ☐ | Accelerated Filer | ☐
Non-Accelerated Filer | ☒ | Smaller Reporting Company | ☒
|  | Emerging Growth Company | ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accountant standards provided pursuant to Section 13(a) of the Exchange Act. Yes ☐ No ☒

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. Yes ☐ No ☒

Indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. Yes ☐ No ☒

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to Section 240.10D-1(b). Yes ☐ No ☒

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of June 30, 2024, the aggregate market value of the registrant’s common stock held by non-affiliates of registrant was $10,228,303 based upon the closing sale price of the common stock as reported by The Nasdaq Capital Market. Solely for purposes of this calculation, all executive officers and directors of the registrant are considered affiliates.

As of September 22, 2025 there were 17,647,130 shares of the Registrant’s common stock outstanding.

DOCUMENTS INCORPORATED BY REFERENCE

List hereunder the following documents if incorporated by reference and the Part of the Form 10-K (e.g., Part I, Part II, Part III) into which the document is incorporated: (1) Any annual report to security holders; (2) Any proxy or information statement; and (3) Any prospectus filed pursuant to Rule 424(b) or (e) under the Securities Act of 1933.

None.

688 Marcum LLP New Jersey

Explanatory Note

Nexalin Technology, Inc. (the “Company”) is filing this Amendment No. 2 on Form 10-K/A (this “Amendment”) to amend the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024 (the “Original Filing”), which was originally filed with the U.S. Securities and Exchange Commission (the “SEC”) on March 14, 2025 (the “Original Filing Date”). The purpose of this Amendment is (i) to correct wording in Management’s Report on Internal Control over Financial Reporting, and (ii) to correct the Exhibits contained in Item 15 of Part IV of the Original Filing to include a previously omitted representation in each of Exhibits 31.1 and 31.2,of each of the Nexalin Technology, Inc. Certifications of the Chief Executive Officer and Chief Financial Officer, respectively, pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended (together the “Certifications”). Because the Certifications are being corrected and refiled, the financial statements for the fiscal year ended as of December 31, 2024, must be refiled.

Except as described above, no changes have been made to the Original Filing, as amended by Amendment No. 1 to the Original Filing (the “Amendment No. 1”), and this Amendment No. 2 does not modify, amend, or update in any way any of the financial or other information contained in the Original Filing, as amended by Amendment No. 1. This Amendment does not reflect events that may have occurred subsequent to the filing dates of the Original Filing or Amendment No. 1. Accordingly, this Amendment should be read in conjunction with the Original Filing, as amended by Amendment No. 1, and the Company’s other filings with the SEC.

Pursuant to Rule 12b-15 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), currently dated and corrected certifications are filed herewith as exhibits to this Amendment pursuant to Rule 13a-14(a) or 15d-14(a) of the Exchange Act. These certifications are attached to this Amendment as Exhibits 31.1 and 31.2 under Item 15 of Part IV hereof. Because financial statements are being filed with this Amendment, certifications pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 have been filed.

TABLE OF CONTENTS

|  | Page
PART II
Item 8. |  | Consolidated Financial Statements and Supplemental Data |  | 1
Item 9A. |  | Controls and Procedures |  | 1
PART IV
Item 15. |  | Exhibits and Financial Statement Schedules |  | 3

i

SPECIAL CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

Certain information included or incorporated by reference in this document may not address historical facts and, therefore, could be interpreted to be “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including projections of financial performance; statements of plans, strategies and objectives of management for future operations; any statement concerning developments, performance or industry rankings relating to products or services; any statements regarding future economic conditions or performance; any statements of assumptions underlying any of the foregoing; and any other statements that address activities, events or developments that Nexalin Technology, Inc. and its subsidiaries (“Nexalin” or the “Company” and also referred to as “we,” “us” and “our”) intends, expects, projects, believes or anticipates will or may occur in the future. Forward-looking statements may be characterized by terminology such as “believe,” “anticipate,” “expect,” “should,” “intend,” “plan,” “will,” “estimates,” “projects,” “strategy” and similar expressions. These statements are based on assumptions and assessments made by the Company’s management in light of its experience and its perception of historical trends, current conditions, expected future developments and other factors it believes to be appropriate. Any such forward-looking statements are not guarantees of future performance (financial or operating), and actual results, developments and business decisions may differ materially from those envisioned by such forward-looking statements. These forward-looking statements are subject to a number of risks and uncertainties that include but are not limited to the following:

| ● | our plans to develop and commercialize our products;

| ● | our planned clinical trials for our products;

| ● | the timing of the availability of data from our clinical trials;

| ● | our ability to take advantage of benefits offered by current and pending legislation related to the development of products addressing antimicrobial resistance;
| ● | the timing of our planned regulatory filings;

| ● | the timing of and our ability to obtain and maintain regulatory approvals for our products;

| ● | the clinical utility of our products and their potential advantages compared to other treatments;

| ● | our commercialization, marketing and distribution capabilities and strategy;

| ● | our ability to establish and maintain arrangements for the manufacture of our products;

| ● | our ability to establish and maintain collaborations and to recognize the potential benefits of such collaborations;

| ● | our estimates regarding the market opportunities for our products;

| ● | our intellectual property position and the duration of our patent rights;

| ● | our estimates regarding future expenses, capital requirements and needs for additional financing; and

the other risk factors set forth under Item 1A, Risk Factors, in this Annual Report on Form 10-K and in our other SEC filings. The forward-looking statements included herein apply only as of the date of this Annual Report on Form 10-K. The Company disclaims any duty to update such forward-looking statements, all of which are expressly qualified by the foregoing, except as may be required by law.

ii

ITEM 8. CONSOLIDATED FINANCIAL STATEMENTS AND SUPPLEMENTAL DATA

See attached Consolidated Financial Statements beginning on page F-1 attached to this Report.

ITEM 9A. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we have evaluated the effectiveness of the design and operation of our “disclosure controls and procedures,” as such term is defined in Rule 13a-15(e) or Rule 15d-15(e) promulgated under the Exchange Act as of the end of the period covered by this Report. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were not effective as of the end of the period covered by this Report to provide reasonable assurance that material information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms due to the material weakness described below.

Management’s Report on Internal Control over Financial Reporting

Management of the Company is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rules 13a-15(f) and 15d-15(f). Internal control over financial reporting is a process designed by, or under the supervision of, our principal executive officer and principal financial officer, or persons performing similar functions, and effected by our board of directors to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with generally accepted accounting principles. Our management evaluated, with the participation of our chief executive officer and chief financial officer (our “Certifying Officers”), the effectiveness of our internal control over financial reporting as of December 31, 2024, pursuant to Rule 13a-15(b) under the Exchange Act. Based upon that evaluation, our Certifying Officers concluded that, as of the evaluation date, our internal control over financial reporting were not effective due to the following material weaknesses:

| ● | Lack of sufficient resources necessary to provide adequate segregation of duties related to the preparation and review of financial information used in financial reporting and review of controls over the financial reporting process; and

| ● | Insufficient IT controls which are effectively designed and implemented, specifically related to user/superuser access to the Company’s financial reporting system.

The deficiencies described above if not remedied, could result in a misstatement of one or more account balances or disclosures in our annual or interim consolidated financial statements that would not be prevented or detected, and, accordingly, we determined that these control deficiencies constitute a material weakness.

To address our material weakness, we intend to implement new financial accounting controls and processes. We intend to continue to take steps to remediate the material weakness described above through implementing enhancements and controls within our accounting systems, subject to budget limitations. We will not be able to remediate these control deficiencies until these steps have been completed and have been operating effectively for a sufficient period of time and Management has concluded, through testing, that the controls are operating effectively. The redesign and implementation of improvements to our accounting and proprietary systems and controls may be costly and time consuming and the cost to remediate may impair our results of operations in the future.

1

In light of the conclusion that our internal control over financial reporting were not effective at December 31, 2024, we have applied particular procedures and processes as necessary to ensure the reliability of our financial reporting with respect to this Report. Accordingly, we believe, based on our knowledge that: (i) this Report does not contain any untrue statement of material fact or omit a statement of material fact necessary to make the statements made, in light of the circumstances under which they were made, not misleading with respect to the period covered by this Report; and (ii) the consolidated financial statements, and other financial information included in this Report, fairly present in all material respects our financial condition, results of operations, and cash flows as of and for the periods presented in this Report.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions or that the degree of compliance with the policies or procedures may deteriorate.

This Report does not include an attestation report of our registered public accounting firm due to an exemption established by SEC rules for emerging growth companies.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) during the most recent fiscal year that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

2

PART IV

Item 15. Exhibits and Financial Statement Schedules

| (a) | Exhibits.

Exhibit Number |  | Description of Document
1.1** |  | Underwriting Agreement dated as of September 15, 2022 between the Registrant and Maxim Group LLC
3.1* |  | Certificate of Incorporation, as amended and as currently in effect.
3.2* |  | Amended and Restated Bylaws.
4.1* |  | Form of Specimen stock certificate evidencing shares of common stock.
4.2*** |  | Warrant Agreement between the Company and Continental Stock Transfer and Trust company as warrant agent dated as of September 16, 2022
4.3*** |  | Form of Warrant Certificate (filed as part of Exhibit 4.2)
5.1* |  | Opinion of Warshaw Burstein, LLP as to legality of the shares.
10.1* |  | Potential Joint Venture Agreement between the Company and Wider Come Limited, and Supplement thereto, dated as of September 21, 2018, as supplemented by Supplement Number 1.
10.2* |  | Employment Agreement between the Company and Mark White dated as of February 15, 2021.
10.3* |  | Agreement between the Company and David Owens, M.D. dated as of February 15, 2021
10.4* |  | Quality Assurance Agreement between the Company and Apical Instruments dated December 31, 2020.
10.5* |  | Advisor Agreement with Leonard Osser dated as of December 22,2021.
10.6* |  | Advisor Agreement with Tucker Anderson dated as of December 24, 2021.
10.7* |  | Advisor Agreement with Gian Domenico Trombetta dated December 24, 2021.
10.8* |  | Employment Agreement between the Company and Marilyn Elson dated as of January 11, 2022
10.9* |  | Amendment and Deferral Agreement dated as of March 30, 2022 to Consulting Agreement between the Company and US Asian Consulting Group LLC
10.10* |  | Employment Agreement between the Company and Michael Nketiah dated as of July 1, 2023.
10.11* |  | Form of Lock-Up Agreement.
10.12* |  | Consulting Agreement dated as of May 9, 2018 as amended between the Company and US Asian Consulting Group, LLC, as amended on January 2, 2019 and March 4, 2021
10.13* |  | Promissory Note in favor Mark White dated as of November 1, 2021, as amended
10.14* |  | Distribution Authorization Agreement dated as of May 1, 2019 with Wider Come Limited.
10.15****** |  | Form of Lock-Up Agreement
10.16****** |  | Form of Securities Purchase Agreement
10.17 ⸹ |  | Placement Agency Agreement
10.18 ⸹⸹ |  | Letter Agreement between the Company and Carolyn Shelton
10.19 ⸹⸹⸹ |  | Supplier Quality Agreement dated as of December 20, 2024 between the Company and Velentium
23.1† |  | Consent of Marcum LLP, independent registered public accounting firm.
23.2* |  | Consent of Warshaw Burstein, LLP (included in Exhibit 5.1).
31.1† |  | Certification of the Chief Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended.
31.2† |  | Certification of the Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended
32.1† |  | Certification of the Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2† |  | Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
99.1* |  | Code of Ethics
99.2* |  | Audit Committee Charter
99.3* |  | Compensation Committee Charter
99.4* |  | Nominating and Corporate Governance Committee Charter
101.INS † |  | Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)
101.SCH † |  | Inline XBRL Taxonomy Extension Schema Document
101.CAL † |  | Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF † |  | Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB † |  | Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE † |  | Inline XBRL Taxonomy Extension Presentation Linkbase Document
104 |  | Cover Page Interactive Data File (formatted in Inline XBRL, and included in exhibit 101).

* | Previously filed as an exhibit to Form S-1 as declared effective by the SEC on September 15, 2022 (SEC File Number 333-261989).
** | Previously filed as an exhibit to Form 8-K as filed with the SEC on September 20, 2022.
*** | Previously filed as an exhibit to Form 8-K/A as filed with the SEC on September 20, 2022
**** | Previously filed as an exhibit to Form 10-Q as filed with the SEC on May 10, 2023
***** | Previously filed as an exhibit to Form 10-Q as filed with the SEC on August 10, 2023
****** | Previously filed as an exhibit to Form S-1/A as declared effective by the SEC on June 27, 2024 (SEC File Number 333-279684)
⸹ | Previously filed as an exhibit to Form 8-K as filed with the SEC on July 3, 2024
⸹⸹ | Previously filed as an exhibit to Form 8-K as filed with the SEC on September 19, 2024
⸹⸹⸹ | Previously filed as an exhibit to Form S-1/A as declared effective by the SEC on February 3, 2025 (SEC File Number 333-283960)
† | Filed as an exhibit to this Amendment No. 2 to Form 10-K for the fiscal year ended December 31, 2024

3

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Amendment No. 2 to the Annual Report on Form 10-K, of Nexalin Technology, Inc. to be signed on its behalf by the undersigned, thereunto duly authorized.

NEXALIN TECHNOLOGY, INC.

By: | /s/ Mark White |
| Mark White |
| Chief Executive Officer |
Date: | September 23, 2025 |

Pursuant to the requirements of the Securities Exchange Act of 1934, this Amendment No. 2 to the Annual Report on Form 10-K, of Nexalin Technology, Inc. has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

By: | /s/ Mark White |
| Mark White |
| Chief Executive Officer |
Date: | September 23, 2025 |
By: | /s/ Justin Van Fleet |
| Justin Van Fleet |
| Chief Financial Officer |
Date: | September 23, 2025 |
By: | /s/ Leslie Bernard |
| Leslie Bernhard |
| Director |
Date: | September 23, 2025 |
By: | /s/ Alan Kazden |
| Alan Kazden |
| Director |
Date: | September 23, 2025 |
By: | /s/ David Owens, M.D. |
| David Owens, M.D. |
| Director |
Date: | September 23, 2025 |
By: | /s/ Ben Hu, M.D. |
| Ben Hu, M.D. |
| Director |
Date: | September 23, 2025 |

4

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

NEXALIN TECHNOLOGY, INC.

CONSOLIDATED FINANCIAL STATEMENTS AS OF DECEMBER 31, 2024 AND 2023

TABLE OF CONTENTS

|  | Page
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM (MARCUM LLP PCAOB FIRM ID 688) |  | F-2
CONSOLIDATED FINANCIAL STATEMENTS: |  |
Consolidated Balance Sheets as of December 31, 2024 and 2023 |  | F-3
Consolidated Statements of Operations and Comprehensive Loss for the Years Ended December 31, 2024 and 2023 |  | F-4
Consolidated Statements of Changes Stockholders’ Equity for the Years Ended December 31, 2024 and 2023 |  | F-5
Consolidated Statements of Cash Flows for the Years Ended December 31, 2024 and 2023 |  | F-6
Notes to Consolidated Financial Statements |  | F-7

F-1

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Shareholders and Board of Directors of

Nexalin Technology, Inc. and Subsidiary

Opinion on the Consolidated Financial Statements

We have audited the accompanying consolidated balance sheets of Nexalin Technology, Inc. and Subsidiary (the “Company”) as of December 31, 2024 and 2023, the related consolidated statements of operations and comprehensive loss, stockholders’ equity and cash flows for each of the years in the two-year period ended December 31, 2024, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the years in the two-year period ended December 31, 2024, in conformity with accounting principles generally accepted in the United States of America.

Explanatory Paragraph – Going Concern

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As more fully described in Note 2, the Company has incurred significant losses and needs to raise additional funds to meet its obligations and sustain its operations. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. Management’s plans in regard to these matters are also described in Note 2. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Basis for Opinion

These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provides a reasonable basis for our opinion.

/s/ Marcum LLP

Marcum LLP

We have served as the Company’s auditor since 2020.

Marlton, New Jersey
March 14, 2025

F-2

NEXALIN TECHNOLOGY, INC. AND SUBSIDIARY

CONSOLIDATED BALANCE SHEETS

|  | December 31, 2024 |  |  | December 31, 2023 |
ASSETS |  |  |  |  |  |  |  |
Current Assets: |  |  |  |  |  |  |  |
Cash and cash equivalents |  | $ | 574,485 |  |  | $ | 580,230 |
Short-term investments |  |  | 2,905,438 |  |  |  | 2,368,203 |
Accounts receivable (Includes related party of $3,007 and $3,614, respectively) |  |  | 13,043 |  |  |  | 9,369 |
Inventory |  |  | 174,578 |  |  |  | 156,420 |
Prepaid expenses and other current assets |  |  | 293,597 |  |  |  | 315,670 |
Total Current Assets |  |  | 3,961,141 |  |  |  | 3,429,892 |
ROU Asset |  |  | - |  |  |  | 496 |
Intangible assets, net |  |  | 260,727 |  |  |  | 105,528 |
Equity Method Investment |  |  | 864 |  |  |  | 96,000 |
Total Assets |  | $ | 4,222,732 |  |  | $ | 3,631,916 |
LIABILITIES AND STOCKHOLDERS’ EQUITY |  |  |  |  |  |  |  |
Current Liabilities: |  |  |  |  |  |  |  |
Accounts payable |  | $ | 155,949 |  |  | $ | 159,534 |
Accrued expenses (Includes related party of $240,000 and $0, respectively) |  |  | 390,745 |  |  |  | 261,284 |
Lease liability, current portion |  |  | - |  |  |  | 4,463 |
Total Current Liabilities |  |  | 546,694 |  |  |  | 425,281 |
Total Liabilities |  |  | 546,694 |  |  |  | 425,281 |
Commitments and Contingencies (Note 8) |  |  |  |  |  |  |  |
Stockholders’ Equity: |  |  |  |  |  |  |  |
Common stock, $0.001 par value; 100,000,000 shares authorized; 13,303,523 and 7,436,562 shares issued and outstanding at December 31, 2024 and December 31, 2023, respectively |  |  | 13,304 |  |  |  | 7,437 |
Accumulated other comprehensive loss |  |  | (513 | ) |  |  | (405 | )
Additional paid in capital |  |  | 88,308,478 |  |  |  | 80,237,652 |
Accumulated deficit |  |  | (84,645,231 | ) |  |  | (77,038,049 | )
Total Stockholders’ Equity |  |  | 3,676,038 |  |  |  | 3,206,635 |
Total Liabilities and Stockholders’ Equity |  | $ | 4,222,732 |  |  | $ | 3,631,916 |

The accompanying footnotes are an integral part of these consolidated financial statements.

F-3

NEXALIN TECHNOLOGY, INC. AND SUBSIDIARY

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

|  | For the Year Ended December 31, |
|  | 2024 |  |  | 2023 |
Revenues, net (Includes related party of $6,180 and $3,614 for the year ended December 31, 2024 and December 31, 2023, respectively) |  | $ | 168,721 |  |  | $ | 110,748 |
Cost of revenues |  |  | 36,593 |  |  |  | 25,688 |
Gross profit |  |  | 132,128 |  |  |  | 85,060 |
Operating expenses: |  |  |  |  |  |  |  |
Professional fees |  |  | 966,815 |  |  |  | 574,598 |
Salaries and benefits |  |  | 1,500,089 |  |  |  | 1,387,916 |
Selling, general and administrative |  |  | 4,228,986 |  |  |  | 1,897,031 |
Research and development |  |  | 1,190,884 |  |  |  | 1,921,811 |
Total operating expenses |  |  | 7,886,774 |  |  |  | 5,781,356 |
Loss from operations |  |  | (7,754,646 | ) |  |  | (5,696,296 | )
Other income (expense), net: |  |  |  |  |  |  |  |
Interest income (expense), net |  |  | 3,193 |  |  |  | (38,835 | )
Gain on sale of short-term investments |  |  | 130,110 |  |  |  | 231,880 |
Other income |  |  | 9,310 |  |  |  | 239,542 |
Gain on extinguishment of debt |  |  | - |  |  |  | 615,000 |
Total other income (expense), net |  |  | 142,613 |  |  |  | 1,047,587 |
Loss before provision for income taxes |  |  | (7,612,033 | ) |  |  | (4,648,709 | )
Provision for income taxes |  |  | - |  |  |  | - |
Loss before equity in net earnings of affiliate |  |  | (7,612,033 | ) |  |  | (4,648,709 | )
Equity in net earnings of affiliate |  |  | 4,851 |  |  |  | - |
Net loss |  |  | (7,607,182 | ) |  |  | (4,648,709 | )
Other comprehensive loss: |  |  |  |  |  |  |  |
Unrealized loss from short-term investments |  |  | (108 | ) |  |  | (36,718 | )
Comprehensive loss |  | $ | (7,607,290 | ) |  | $ | (4,685,427 | )
Net loss per share attributable to common stockholders - Basic and Diluted |  | $ | (0.83 | ) |  | $ | (0.63 | )
Weighted Average Shares Outstanding - Basic and Diluted |  |  | 9,215,772 |  |  |  | 7,357,029 |

The accompanying footnotes are an integral part of these consolidated financial statements.

F-4

NEXALIN TECHNOLOGY, INC. AND SUBSIDIARY

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY

|  | Common Stock |  |  | Accumulated Other Comprehensive |  |  | Additional Paid-in |  |  | Accumulated |  |  | Total Stockholders’ Equity |
|  | Shares |  |  | Amount |  |  | Gain (Loss) |  |  | Capital |  |  | Deficit |  |  | (Deficit) |
Balance as January 1, 2023 |  |  | 7,286,562 |  |  | $ | 7,287 |  |  | $ | 36,313 |  |  | $ | 77,824,427 |  |  | $ | (72,389,340 | ) |  | $ | 5,478,687 |
Stock compensation |  |  | 150,000 |  |  |  | 150 |  |  |  | - |  |  |  | 2,413,225 |  |  |  | - |  |  |  | 2,413,375 |
Other comprehensive loss |  |  | - |  |  |  | - |  |  |  | (36,718 | ) |  |  | - |  |  |  | - |  |  |  | (36,718 | )
Net loss |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | (4,648,709 | ) |  |  | (4,648,709 | )
Balance as of December 31, 2023 |  |  | 7,436,562 |  |  | $ | 7,437 |  |  | $ | (405 | ) |  | $ | 80,237,652 |  |  | $ | (77,038,049 | ) |  | $ | 3,206,635 |

|  | Common Stock |  |  | Accumulated Other Comprehensive |  |  | Additional Paid-in |  |  | Accumulated |  |  | Total Stockholders’ |
|  | Shares |  |  | Amount |  |  | Gain (Loss) |  |  | Capital |  |  | Deficit |  |  | Equity |
Balance as of January 1, 2024 |  |  | 7,436,562 |  |  | $ | 7,437 |  |  | $ | (405 | ) |  | $ | 80,237,652 |  |  | $ | (77,038,049 | ) |  | $ | 3,206,635 |
Stock issued for cash |  |  | 3,000,000 |  |  |  | 3,000 |  |  |  | - |  |  |  | 4,513,184 |  |  |  | - |  |  |  | 4,516,184 |
Other comprehensive loss |  |  | - |  |  |  | - |  |  |  | (108 | ) |  |  | - |  |  |  | - |  |  |  | (108 | )
Stock compensation |  |  | 2,866,961 |  |  |  | 2,867 |  |  |  | - |  |  |  | 3,557,642 |  |  |  | - |  |  |  | 3,560,509 |
Net loss |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | (7,607,182 | ) |  |  | (7,607,182 | )
Balance as of December 31, 2024 |  |  | 13,303,523 |  |  | $ | 13,304 |  |  | $ | (513 | ) |  | $ | 88,308,478 |  |  | $ | (84,645,231 | ) |  | $ | 3,676,038 |

The accompanying footnotes are an integral part of these consolidated financial statements.

F-5

NEXALIN TECHNOLOGY, INC. AND SUBSIDIARY

CONSOLIDATED STATEMENTS OF CASH FLOWS

|  | For the Year Ended December 31, |
|  | 2024 |  |  | 2023 |
Cash flows from operating activities: |  |  |  |  |  |  |  |
Net loss |  | $ | (7,607,182 | ) |  | $ | (4,648,709 | )
Adjustments to reconcile net loss to net cash used in operating activities: |  |  |  |  |  |  |  |
Stock compensation |  |  | 3,560,509 |  |  |  | 2,413,375 |
Depreciation |  |  | - |  |  |  | 503 |
Amortization |  |  | 15,107 |  |  |  | 3,751 |
Non-cash lease expense |  |  | 496 |  |  |  | 5,675 |
Write off of inventory |  |  | - |  |  |  | 5,762 |
Gain on sale of short-term investments |  |  | (130,110 | ) |  |  | (231,880 | )
Return on investment in Joint Venture |  |  | 95,136 |  |  |  | - |
Extinguishment of debt - note payable |  |  | - |  |  |  | (615,000 | )
Changes in operating assets and liabilities: |  |  |  |  |  |  |  |
Accounts receivable |  |  | - |  |  |  | (880 | )
Accounts receivable - related party |  |  | (3,674 | ) |  |  | (3,614 | )
Prepaid assets |  |  | 22,073 |  |  |  | (43,388 | )
Inventory |  |  | (18,158 | ) |  |  | (7,812 | )
Accounts payable - related party |  |  | - |  |  |  | (260,000 | )
Accounts payable |  |  | (3,585 | ) |  |  | (238,833 | )
Accrued expenses |  |  | (110,539 | ) |  |  | (163,538 | )
Accrued expenses - related party |  |  | 240,000 |  |  |  | - |
Lease liability |  |  | (4,463 | ) |  |  | (50,797 | )
Net cash (used in) provided by operating activities |  |  | (3,944,390 | ) |  |  | (3,835,384 | )
Cash flows from investing activities: |  |  |  |  |  |  |  |
Sale of short-term investments |  |  | 33,224,000 |  |  |  | 41,278,241 |
Purchase of short-term investments |  |  | (33,631,233 | ) |  |  | (36,620,090 | )
Investment in Equity Method Investment |  |  | - |  |  |  | (96,000 | )
Purchase of patents |  |  | (116,812 | ) |  |  | (98,970 | )
Purchase of trademarks |  |  | (53,494 | ) |  |  | (10,309 | )
Net cash (used in) provided by investing activities |  |  | (577,539 | ) |  |  | 4,452,872 |
Cash flows from financing activities: |  |  |  |  |  |  |  |
Sale of common stock for cash, net of financing fees |  |  | 4,516,184 |  |  |  | - |
Payments on notes payable - officer |  |  | - |  |  |  | (200,000 | )
Net cash (used in) provided by financing activities |  |  | 4,516,184 |  |  |  | (200,000 | )
Net increase (decrease) in cash and cash equivalents |  |  | (5,745 | ) |  |  | 417,487 |
Cash and cash equivalents - beginning of year |  |  | 580,230 |  |  |  | 162,743 |
Cash and cash equivalents - end of year |  | $ | 574,485 |  |  | $ | 580,230 |
Non-cash investing and financing activities: |  |  |  |  |  |  |  |
Unrealized loss on short-term investments |  | $ | (108 | ) |  | $ | (36,718 | )

The accompanying footnotes are an integral part of these consolidated financial statements.

F-6

NEXALIN TECHNOLOGY, INC. AND SUBSIDIARY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 — NATURE OF THE ORGANIZATION AND BUSINESS

Corporate History

Nexalin Technology, Inc. (“NV Nexalin”) was formed on October 19, 2010 as a Nevada corporation. The Company’s principal offices are located at 1776 Yorktown, Suite 550, Houston, Texas 77056.

On September 6, 2019, Neuro-Health International, Inc. (“Neuro-Health”), a Nevada corporation, a wholly owned subsidiary of NV Nexalin, was formed. Neuro-Health had no activity from December 6, 2019 (Inception) through December 31, 2023.

On November 22, 2021, NV Nexalin entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Nexalin Technology, Inc., a Delaware corporation (“Nexalin”, or the “Company”). Pursuant to the Merger Agreement, NV Nexalin merged with and into Nexalin with all shareholders of NV Nexalin receiving one common share of Nexalin in exchange for twenty shares of NV Nexalin held at the time of the Merger Agreement. NV Nexalin treated the transaction as a corporate reorganization with the historical consolidated financial statements of NV Nexalin becoming the historical consolidated financial statements of Nexalin. Nexalin had nominal assets and liabilities and did not conduct any operations prior to the reorganization other than its incorporation. NV Nexalin has retroactively applied the 20-for-1 exchange, effective on November 22, 2021, to share and per share amounts on the audited consolidated financial statements for the years ended December 31, 2024 and 2023. NV Nexalin’s authorized shares of common stock were not affected as a result of the Merger Agreement. As a result of the Merger Agreement, NV Nexalin was dissolved, and Neuro-Health became a subsidiary of Nexalin. The Company completed its initial public offering on September 16, 2022.

The initial public offering consisted of 2,315,000 units consisting of 2,315,000 shares of common stock and 2,315,000 accompanying warrants to purchase up to 2,315,000 shares of common stock. Each share of common stock was sold together with one warrant, each to purchase one share of common stock with an exercise price of $4.15 per share at a combined offering price of $4.15, for gross proceeds of $9,607,250, before deducting underwriting discounts and offering expenses. In addition, the underwriters purchased 347,250 warrants for net proceeds of $3,473.

Our shares and warrants began trading on the Nasdaq Capital Market tier of the Nasdaq Stock Market (“Nasdaq”) on September 16, 2022, under the symbols “NXL” and “NXLIW”, respectively.

Throughout this Report, the terms “Nexalin,” “our,” “we,” “us,” and the “Company” refer to Nexalin Technology, Inc.

Business Overview

We design and develop innovative neurostimulation products to uniquely and effectively help combat the ongoing global mental health epidemic. We developed an easy-to-administer medical device — referred to as “Generation 1” or “Gen-1” — that utilizes bioelectronic medical technology to treat anxiety, insomnia and depression without the need for drugs or psychotherapy. Our original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit a waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (the “FDA”) as a Class II device.

Medical professionals in the United States have utilized the Gen-1 device to administer treatment to patients in clinical settings. While the Gen-1 device had been cleared by the FDA to treat depression, anxiety, and insomnia, three prevalent and serious diseases, because of the FDA’s December 2019 reclassification of CES devices, the Gen-1 device was reclassified as a Class II device for the treatment of anxiety and insomnia. We are required to file a new application under Section 510(k) of the Federal Food, Drug and Cosmetic Act (“510(k) Application”) to be approved by the FDA for the sales and marketing of our devices for the treatment of anxiety and insomnia. In the FDA’s December 2019 reclassification ruling, the treatment of depression with our device will require a Class III certification and require a new PMA (premarket approval) and/or a new De Novo application to demonstrate safety and effectiveness.

F-7

While we continue providing services to medical professionals to support patients’ use of the Gen-1 devices which were in operation prior to December 2019, we are not making new sales or new marketing efforts of Gen-1 devices in the United States. We continue to derive revenue from devices which we sold or leased prior to the FDA’s December 2019 reclassification announcement. This revenue consists of monthly licensing fees and payments for the sale of electrodes and patient cables. We have paused marketing efforts for new sales of our Gen-1 device for treatment of anxiety and insomnia in the United States. Our regulatory team continues have discussions with the FDA regarding the suspension of the marketing and sale of the Gen-1 products to new providers.

The waveform that comprises the basis of our “Generation 2” or “Gen-2” and new “Generation 3” or “Gen-3” headset devices is in Q-submission process for review by the FDA. This process allows Nexalin to get clear, specific, written feedback from the FDA on indications, device classification and clarity on the regulatory pathway and improves the efficiency and predictability of the regulatory pathway. Determinations of the safety and efficacy of our devices in the United States are solely within the authority of the FDA. We plan to conduct decentralized clinical trials for the Gen-3 device in the U.S. and we continue to consult with the FDA as part of the pre-submission process. If and when we obtain FDA clearance for the Gen-3 device, we intend to extend the development and commercialization of our devices for sale in the U.S. and other territories, given the potential unmet demand for the treatment of mental health conditions with our device.

We have designed and developed a new advanced waveform technology to be emitted at 15 milliamps through new and improved medical devices referred to as Gen-2 and Gen-3. Gen-2 is a clinical use device with a modern enclosure to emit the new 15 milliamp advanced waveform. Gen-3 is a new patient headset that will be prescribed by licensed medical professionals in a virtual clinic setting similar to existing tele-health platforms. The Nexalin research team believes that the new 15 milliamp Gen-2 and Gen-3 devices can penetrate deeper into the brain and stimulate associated structures that contribute to or cause mental illness, which we believe will generate enhanced patient response without any risk or unpleasant side effects. The Nexalin regulatory team has made a strategic decision to develop strategies for pilot trials and/or pivotal trials in various mental health disease states. In addition, a new PMA application in the United States is in strategic development for the treatment of depression utilizing both Gen-2 and Gen-3. We plan to develop a strategic schedule to execute additional pilot trials and/or pivotal trials for the new Gen-3 device for anxiety and insomnia in the United States, Brazil and China beginning in the first quarter of 2025. Preliminary data provided by The University of California, San Diego and recent published data from Asia supports the safety of utilizing our 15 milliamp waveform technology. However, the determination of safety and efficacy of medical devices in the United States is subject to clearance by the FDA.

Currently, the waveform that comprises the basis of Gen-2 and new Gen-3 headset devices has been tested in research settings to develop safety data that has been submitted for review by the FDA for safety evaluation and eventual marketing in the United States and around the world. Determinations of the safety and efficacy of our devices in the United States are solely within the authority of the FDA.

A new pre-submission document in preparation of a new 510(k) and/or De Novo application for our Gen-3 HALO headset at 15 milliamps was filed with the FDA in January of 2023. Formal comments to our pre-submission document filing were received in March of 2023. A formal meeting to address FDA comments took place on May 9, 2023.

A second FDA pre-submission document was submitted on February 13, 2024. FDA comments to this second pre-submission document were received on April 26, 2024. A formal teleconference was held with the FDA on April 26, 2024. The Nexalin regulatory team and the FDA came to a consensus on the Insomnia Clinical research protocols for insomnia assessment scales and timeline end points and patient population size.

Data from these clinical trials will also be used to support an application for the CE-mark of our Gen-2 and new Gen-3 headset devices in the European Union.

On May 31, 2023, the Company formalized an agreement related to the formation of a joint venture established to engage in the clinical development, marketing, sale and distribution of Nexalin’s second generation transcranial Alternating Current Stimulation (“tACS”) devices (“Gen-2 devices”) in China and other countries in the region. The Joint Venture is registered in Hong Kong.

As of the date of this Report, (i) we have no employees or offices in China and none of our operations are conducted in China; and (ii) the Joint Venture does not maintain any variable interest entity structure or operate any data center in China.

Under the Joint Venture Agreement, Wider is obligated to fund all operations for the initial 12-month period of the Joint Venture, after which Nexalin and Wider plan to jointly fund the Joint Venture’s operating expenses in accordance with their pro rata ownership.

F-8

The Joint Venture is controlled by a Board of Directors in which Wider is to have sole representation but neither the Company nor Wider has exclusive decision-making ability over day-to-day or significant operational decisions. Wider and Nexalin own 52% and 48% of the Joint Venture, respectively. In accordance with ASC 323 and ASC 810, the Company recognized $4,851 and $0 for the years ended December 31, 2024 and 2023, respectively, on the consolidated statements of operations and comprehensive loss.

The investment in the Joint Venture is accounted for using the equity method of accounting. As of December 31, 2024 and 2023 the Company had an Equity Method Investment of $864 and $96,000, respectively, recorded on the consolidated balance sheets. The Company invested $96,000 in the joint venture in September 2023 and Wider invested $104,000. In accordance with ASC 323, the Company uses the equity method of accounting for its investment in the Joint Venture, an unconsolidated entity over which it does not have a controlling interest. The equity method of accounting requires the investment to be initially recorded at cost and subsequently adjusted for the Company’s share of equity in the unconsolidated entity’s earnings or losses. The Company evaluates the carrying amount of this investment in the Joint Venture for impairment in accordance with ASC 323. If the Company determines that a loss in the value of the investment is other than temporary, the Company writes down the investment to its estimated fair value. Any such losses are recorded to equity in income of unconsolidated entities in the Company’s consolidated statements of operations and comprehensive loss. The Company has made an election to classify distributions received from the Joint Venture using the nature of the distribution approach. Distributions received are classified as cash inflows from operating activities based on the nature of the activities of the unconsolidated entity.

Emerging Growth Company

The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and approval of any golden parachute payments not previously approved. Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s consolidated financial statements with another public company which is neither an emerging growth company, nor an emerging growth company which has opted out of using the extended transition period, difficult or impossible because of the potential differences in accounting standards used.

Risks and Uncertainties

Management continues to evaluate the impact of the economy and the capital markets and has concluded that, while it is reasonably possible that events could have negative effects on the Company’s financial position and results of its operations, the specific impacts are not readily determinable as of the date of these consolidated financial statements. The consolidated financial statements do not include any adjustments that might result from the outcome of uncertainties.

The current challenging economic climate may lead to adverse changes in cash flows, working capital levels and/or debt balances, which may also have a direct impact on the Company’s operating results and financial position in the future. The ultimate duration and magnitude of the impact and the efficacy of government interventions on the economy has and may continue to indirectly impact the Company because of its current dependence upon its joint venture relationship with Wider Come Limited. Wider Come Limited, as part of its obligations under the Joint Venture Agreement, acts as a distributor for the Company’s devices in China and Asia. Because of significant restrictions imposed by the Chinese government during the COVID-19 pandemic through calendar year 2022 and into 2023, Wider’s ability to market and sell the Company’s devices was negatively impacted, resulting in decreased revenue to the Company. Patients and salespeople have been restricted in their movements resulting in a significant slowdown in the medical and other sectors. Significant efforts and funds expended by our Chinese distributor has led to regulatory approval in China in both depression and insomnia thus far which has allowed for sales of our devices in China in 2022, and into 2023. The extent of future impact is dependent on future developments, including future activities by the Chinese government and other possible events which are highly uncertain and not in the Company’s control, including new information which may emerge, or any of its variants, and actions taken to address its impact, among others. The repercussions of this health crisis could have a material adverse effect on the Company’s business, financial condition, liquidity and operating results.

F-9

Continued Nasdaq Listing

Our shares of our common stock are listed on the Capital Market tier of the Nasdaq Stock Market, or Nasdaq, under the symbol “NXL.” Nasdaq has rules for continued listing, including, without limitation, minimum market capitalization, minimum stockholders’ equity and other requirements. In order to maintain that listing, we must satisfy minimum financial and other continued listing requirements and standards, including the Minimum Bid Price Rule (as discussed below) and those regarding director independence and independent committee requirements, minimum stockholders’ equity, and certain corporate governance requirements. There can be no assurances that we will be able to comply with the applicable listing standards.

Minimum Bid Price Requirement

We are required to maintain a minimum bid price of $1.00 per share. On May 10, 2023, the Company received written notice from Nasdaq notifying the Company that it was no longer in compliance with the minimum bid price requirement for continued listing on Nasdaq, as the closing bid price for the Company’s common stock was below $1.00 per share as set forth in the Nasdaq listing rules. The Company was afforded 180 calendar days, or until November 6, 2023, to regain compliance with the Nasdaq listing rules. The Company was unable to regain compliance with the bid price requirement by November 6, 2023.

The Company requested a second 180-day period in order to regain compliance with Nasdaq Rule 5550(a)(2). On January 18, 2024, the Nasdaq Hearing Panel granted the Company a temporary exception to regain compliance with the Minimum Bid Price Rule until March 27, 2024, which date was further extended by the Panel until April 25, 2024. On April 23, 2024, the Company received notice from Nasdaq notifying the Company that it has regained compliance with Nasdaq’s minimum bid price requirement under Nasdaq Rule 5550(a)(2).

On September 23, 2024, we received a notice from Nasdaq notifying us that we were not in compliance with the Minimum Bid Price Rule. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), we had 180 calendar days, or until March 24, 2025, to regain compliance with Nasdaq Listing Rule 5450(a)(1). To regain compliance, the closing bid price of our common stock must be at least $1.00 per share for a minimum of 10 consecutive business days. On October 31, 2024, the Company received notice from Nasdaq notifying the Company that it has regained compliance with Nasdaq’s minimum bid price requirement under Nasdaq Rule 5550(a)(2).

Minimum Stockholder Equity Requirement

Under the Nasdaq listing rules, we are also required to maintain stockholders’ equity of at least $2,500,000 (the “Minimum Stockholder Equity Rule”). In our Form 10-Q for the period ending March 31, 2024, we reported stockholders’ equity of $2,326,987. On May 16, 2024, we received a letter from the Listing Qualifications Department of Nasdaq notifying the Company that its stockholders’ equity as reported in such Quarterly Report did not satisfy the continued listing requirement under Nasdaq Listing Rule 5550(b)(1) for the Nasdaq Capital Market.

Pursuant to the Notice, the Company had 45 calendar days from the date of the Notice to submit a plan to regain compliance. On July 1, 2024, the Company submitted a plan to Nasdaq. As described in the Company’s submission to Nasdaq, and as set forth in the Current Report on Form 8-K filed by the Company on July 3, 2024, the Company consummated the public offering of 3 million shares of the Company’s common stock for total aggregate gross proceeds of approximately $5,250,000. On July 23, 2024, the Company received written notification from the Listing Qualifications Department of Nasdaq, confirming that, based on the information contained in the Company’s Form 8-K, filed with the SEC on July 16, 2024, the Company is now in compliance with the Minimum Stockholder Equity Rule.

If the Company’s common stock and warrants are delisted by Nasdaq, it could adversely affect the Company’s ability to attract new investors, decrease the liquidity of the outstanding shares of common stock, reduce the Company’s flexibility to raise additional capital, reduce the price at which the Company’s common stock and warrants trade, and increase the transaction costs inherent in trading such shares and warrants with overall negative effects for the stockholders. In addition, delisting of the Company’s common stock and warrants could deter broker-dealers from making a market in or otherwise seeking or generating interest in the Company’s common stock. Furthermore, the delisting of the Company’s common stock and warrants from The Nasdaq Stock Market could adversely affect the business, financial condition and results of operations of the Company.

F-10

NOTE 2 — LIQUIDITY AND GOING CONCERN

The accompanying audited consolidated financial statements have been prepared on the basis that the Company will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business. At December 31, 2024, the Company had a significant accumulated deficit of approximately (84,645,231) $84.6 million. For the year ended December 31, 2024, the Company had a loss from operations of approximately (7,754,646) $7.8 million and negative cash flows from operations of approximately (3,944,390) $3.9 million. While the Company had a working capital surplus as of December 31, 2024 of approximately $3.4 million, the Company’s operating activities consume most of its cash resources.

The Company expects to continue to incur operating losses as it executes its development plans, as well as undertaking other potential strategic and business development initiatives through 2025 and through the twelve months from the date of this Report. In addition, the Company has had and expects to have negative cash flows from operations, at least into the near future. The Company previously funded these losses primarily through the sale of equity and issuance of convertible notes. These factors, among others, raise substantial doubt about the ability of the Company to continue as a going concern for a reasonable period.

Our ability to continue as a going concern will be dependent upon our ability to execute on our business plan, including the ability to generate revenue from the joint venture and obtain U.S. approval for the sale of our devices in the United States, and, if necessary, our ability to raise additional capital. Although no assurances can be given as to our ability to deliver on our revenue plans or that unforeseen expenses may arise, management has evaluated the significance of the conditions as of December 31, 2024 and have concluded that we will not have sufficient cash and short-term investments to satisfy our anticipated cash requirements for the next twelve months from the issuance of these financial statements. The accompanying audited consolidated financial statements do not include any adjustments that might be necessary should we be unable to continue as a going concern.

NOTE 3 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND NEW ACCOUNTING STANDARDS

Basis of Presentation

The accompanying audited consolidated financial statements have been prepared in accordance with Generally Accepted Accounting Principles in the United States (“GAAP”). In the opinion of management, such financial information includes all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of the Company’s financial position and the operating results and cash flows. Operating results for the years ended December 31, 2024 and 2023 are not necessarily indicative of the results that may be expected for future years or for any other subsequent interim period. Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with GAAP have been omitted pursuant to the rules of the U.S. Securities and Exchange Commission (the “SEC”).

Principles of Consolidation

The consolidated financial statements include the accounts of Nexalin and its wholly owned subsidiary Neuro-Health. Intercompany accounts and transactions have been eliminated in consolidation.

Use of Estimates

The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, equity-based transactions, revenue and expenses and disclosure of contingent liabilities at the date of the consolidated financial statements. The Company bases its estimates and assumptions on historical experience, known or expected trends and various other assumptions that it believes to be reasonable. As future events and their effects cannot be determined with precision, actual results could differ from these estimates, which may cause the Company’s future results to be affected.

F-11

Revenue

The Company recognizes revenue when its performance obligations with its customers have been satisfied. At contract inception, the Company determines if the contract is within the scope of Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers, and then evaluates the contract using the following five steps: (1) identify the contract with the customer; (2) identify the performance obligations; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations; and (5) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only recognizes revenue to the extent that it is probable that a significant revenue reversal will not occur in a future period.

The Company has existing licensing and treatment fee agreements with its customers for the use of the Nexalin Device in their practices. These agreements generally have terms of one year with automatic renewal if certain requirements are met and amounts due per these agreements are billed monthly. The Company also sells products related to the provision of services. The Company sells its Devices in China to its acting distributor and sells products relating to the use of the Devices. The Company has a Royalty Agreement whereby the manufacturer of the Company’s electrodes pays a royalty to the Company for a three-year period beginning January 1, 2022. The amount of the Royalty is equal to 20% of the amount that the manufacturer invoices to the acting distributor for the sale of the electrodes.

Revenue Streams

The Company derives revenues from our license agreements by charging a monthly licensing fee for the duration of the agreement. The Company derives revenues from equipment by selling additional individual electrodes to customers for use with the Nexalin Device. We receive revenue from the sale in China of our Devices to our distributor and from the sale of products relating to the use of those Devices. We derive revenue as a royalty fee from the China-based manufacturer for electrodes ordered in connection with our China sales.

Performance Obligations

Management identified that subsequent licensing revenue has one performance obligation. That performance obligation is satisfied if the licensing contract remains valid and is not terminated. The licensing revenue is invoiced monthly and is recognized at a point in time in which the invoice is sent to the customer.

Management identified that the Company’s equipment and Device revenue has one performance obligation. That performance obligation is satisfied when the equipment and Devices are shipped. The Company recognizes revenue at a point in time in which the equipment and Devices are shipped to the customer. The Company does not offer a warranty on the equipment or Devices.

Management identified that treatment fee revenue has one performance obligation. The performance obligation is satisfied upon the completion of individual treatments on patients by customers.

Management identified that royalty revenue has one performance obligation. The performance obligation is satisfied at the time the Electrode manufacturer notifies the Company that it has invoiced the distributor for the sale to the distributor.

Practical Expedients

As part of ASC 606, the Company has adopted several practical expedients including:

| ● | Significant Financing Component — the Company does not adjust the promised amount of consideration for the effects of a significant financing component since the Company expects, at contract inception, that the period between when the Company transfers promised goods or services to the customer and when the customer pays for that service will be one year or less.

F-12

| ● | Unsatisfied Performance Obligations — for all performance obligations related to contracts with a duration of less than one year, the Company has elected to apply the optional exemption provided in ASC Topic 606 and therefore, is not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period.

| ● | Shipping and Handling Activities — the Company elected to account for shipping and handling activities as a fulfilment cost rather than as a separate performance obligation.

| ● | Right to invoice — the Company has a right to consideration from a customer in an amount that corresponds directly with the value to the customer of the Company’s performance completed to date; the Company may recognize revenue in the amount to which the entity has a right to invoice.

Disaggregated Revenues

Major Revenue Streams

Revenue consists of the following by service offering:

Schedule of disaggregation of revenue |  |  |  |  |  |  |  |
|  | Years Ended December 31, |
|  | 2024 |  |  | 2023 |
Device sales |  | $ | 55,500 |  |  | $ | - |
Licensing fee |  |  | 69,501 |  |  |  | 82,080 |
Equipment |  |  | 37,826 |  |  |  | 27,299 |
Other |  |  | 5,894 |  |  |  | 1,369 |
Total |  | $ | 168,721 |  |  | $ | 110,748 |

Major Geographic Locations

|  | Years Ended December 31, |
|  | 2024 |  |  | 2023 |
U.S. sales |  | $ | 83,473 |  |  | $ | 107,134 |
China sales |  |  | 85,248 |  |  |  | 3,614 |
Total |  | $ | 168,721 |  |  | $ | 110,748 |

Contract Modifications

There were no contract modifications during the years ended December 31, 2024 and 2023. Contract modifications are not routine in the performance of the Company’s contracts.

F-13

Deferred Revenue

The Company receives payment for equipment and devices in advance of shipping. The Company recognizes the revenue as being earned upon shipment. No deferred revenue was recognized as of December 31, 2024 and December 31, 2023.

Cash and Cash Equivalents

The Company considers all highly liquid investments with maturities of three months or less at the time of purchase to be cash equivalents. Cash and cash equivalents held at financial institutions may at times exceed insured amounts. The Company believes it mitigates such risk by investing in or through, as well as maintaining cash balances with, with major financial institutions.

Short-Term Investments

The appropriate classification of marketable securities is determined at the time of purchase and evaluated as of each reporting balance sheet date. Investments in marketable debt and equity securities classified as available-for-sale are reported at fair value. Fair value is determined using quoted market prices in active markets for identical assets or liabilities or quoted prices for similar assets or liabilities or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Unrealized holding gains and losses for equity securities are recognized in earnings. Unrealized holding gains and losses for available for sale debt securities are recognized in other comprehensive income (loss.) Realized gains and losses and interest and dividends earned are included in other income (expense), net. For individual debt securities classified as available-for-sale securities, the Company determines whether a decline in fair value below the amortized cost basis has resulted from a credit loss or other factors. If the decline below amortized cost is a result of credit loss or the Company will more likely than not be required to sell the security before recovery of its amortized cost basis, the Company will recognize an impairment relating to the decline through an allowance for credit losses. There were no deemed permanent impairments at December 31, 2024 or 2023.

Accounts Receivable

Accounts receivables are reported at their outstanding unpaid principal balances, net of allowances for credit loss. The Company periodically assesses its accounts and other receivables for collectability on a specific identification basis. The Company provides for an allowance for credit loss based on management’s estimate of uncollectible amounts considering age, collection history, and any other factors considered appropriate. Payments are generally due within 30 days of invoice. The Company writes off accounts receivable against the allowance for credit loss when a balance is determined to be uncollectible. During the year ended December 31, 2024 and 2023 the Company did not write off, accounts receivable. The Company did not record an allowance for credit loss as of December 31, 2024 and 2023, respectively.

Inventory

Inventory consists of finished goods and components stated at the lower of cost or net realizable value (NRV) with cost determined on a first-in first-out basis. The Company reviews the composition of inventory at each reporting period in order to identify obsolete quantities in excess of demand, or otherwise non-saleable items. At December 31, 2024 and 2023, the Company wrote down inventory in the amount of $0 and $5,762 respectively to its NRV.

Patents and Trademarks

Patents and trademarks are amortized over their useful lives and are reviewed for impairment when warranted by economic conditions. Amortization expense was $15,107 and $3,751 for the year ended December 31, 2024 and 2023, respectively.

F-14

The following table summarizes the gross carrying amount, amortization and the net carrying value at December 31, 2024 and December 31, 2023.

Schedule of patents |  |  |  |  |  |  |  |  |  |  |  |
|  | Gross Carrying Amount |  |  | Accumulated Amortization |  |  | Net Carrying Value |
December 31, 2024 |  |  |  |  |  |  |  |  |  |  |  |
Patents |  | $ | 215,782 |  |  | $ | (13,519 | ) |  | $ | 202,263 |
Trademarks |  |  | 64,067 |  |  |  | (5,603 | ) |  |  | 58,464 |
Total December 31, 2024 |  | $ | 279,849 |  |  | $ | (19,122 | ) |  | $ | 260,727 |
December 31, 2023 |  |  |  |  |  |  |  |  |  |  |  |
Patents |  | $ | 98,970 |  |  | $ | (3,751 | ) |  | $ | 95,219 |
Trademarks |  |  | 10,573 |  |  |  | (264 | ) |  |  | 10,309 |
Total December 31, 2023 |  | $ | 109,543 |  |  | $ | (4,015 | ) |  | $ | 105,528 |

Income Taxes

The Company accounts for income taxes pursuant to the asset and liability method which requires the recognition of deferred income tax assets and liabilities related to the expected future tax consequences arising from temporary differences between the carrying amounts and tax bases of assets and liabilities based on enacted statutory tax rates applicable to the periods in which the temporary differences are expected to reverse. Any effects of changes in income tax rates or laws are included in income tax expense in the period of enactment.

The Company records valuation allowances against deferred tax assets when it is more likely than not that all or a portion of a deferred tax asset will not be realized. At December 31, 2024 and 2023, the Company had a full valuation allowance applied against its deferred net tax assets.

Fair Value Measurements

As defined in ASC 820, Fair Value Measurements and Disclosures, fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company utilizes market data or assumptions that market participants would use in pricing the asset or liability, including assumptions about risk and the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market corroborated, or generally unobservable. ASC 820 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurement) and the lowest priority to unobservable inputs (level 3 measurement). This fair value measurement framework applies at both initial and subsequent measurement.

| ● | Level 1: Quoted prices are available in active markets for identical assets or liabilities as of the reporting date. Active markets are those in which transactions for the asset or liability occur in sufficient frequency and volume to provide pricing information on an ongoing basis.

| ● | Level 2: Pricing inputs are other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reported date. Level 2 includes those financial instruments that are valued using models or other valuation methodologies. These models are primarily industry-standard models that consider various assumptions, including quoted forward prices for commodities, time value, volatility factors and current market and contractual prices for the underlying instruments, as well as other relevant economic measures. Substantially all these assumptions are observable in the marketplace throughout the full term of the instrument, can be derived from observable data or are supported by observable levels at which transactions are executed in the marketplace.

F-15

| ● | Level 3: Pricing inputs include significant inputs that are generally less observable from objective sources. These inputs may be used with internally developed methodologies that result in management’s best estimate of fair value. The significant unobservable inputs used in the fair value measurement for nonrecurring fair value measurements of long-lived assets include pricing models, discounted cash flow methodologies and similar techniques.

Fair Value of Financial Instruments

The carrying value of cash, short-term investments, accounts receivable, inventory, prepaids, accounts payable and accrued expenses, and other current liabilities approximate their fair values based on the short-term maturity of these instruments. The carrying amount of the loans payable approximates the estimated fair value for this financial instrument as management believes that such debt and interest payable on the note approximates the Company’s incremental borrowing rate.

The following table summarizes the amortized cost, unrealized loss and the fair value at December 31, 2024 and 2023:

Schedule of unrealized loss on investments |  |  |  |  |  |  |  |  |  |  |  |
|  | Amortized Cost |  |  | Unrealized Loss |  |  | Fair Value |
December 31, 2024 |  |  |  |  |  |  |  |  |  |  |  |
Short-term investments |  | $ | 2,905,951 |  |  | $ | (513 | ) |  | $ | 2,905,438 |
December 31, 2023 |  |  |  |  |  |  |  |  |  |  |  |
Short-term investments |  | $ | 2,368,608 |  |  | $ | (405 | ) |  | $ | 2,368,203 |

The following table provides the carrying value and fair value of the Company’s financial assets measured at fair value as of December 31, 2024 and 2023:

Schedule of fair value, assets measured on recurring basis |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  | Carrying Value |  |  | Level 1 |  |  | Level 2 |  |  | Level 3 |
December 31, 2024 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
U.S. Treasury Bill |  | $ | 2,650,225 |  |  | $ | 2,650,225 |  |  | $ | - |  |  | $ | - |
Mutual Funds |  |  | 255,213 |  |  |  | 255,213 |  |  |  | - |  |  |  | - |
Total December 31, 2024 |  | $ | 2,905,438 |  |  | $ | 2,905,438 |  |  | $ | - |  |  | $ | - |
December 31, 2023 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
U.S. Treasury Bill |  | $ | 2,368,203 |  |  | $ | 2,368,203 |  |  | $ | - |  |  | $ | - |

As defined in ASC 820, Fair Value Measurements and Disclosures, fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company utilizes market data or assumptions that market participants would use in pricing the asset or liability, including assumptions about risk and the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market corroborated, or generally unobservable. ASC 820 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurement) and the lowest priority to unobservable inputs (level 3 measurement). This fair value measurement framework applies at both initial and subsequent measurement for the year ended December 31, 2024 and 2023.

Net Loss per Common Share

Net loss per common share is computed by dividing the net loss by the weighted average number of common shares outstanding during the period. The dilutive effect, if any, of stock options and warrants is calculated using the treasury stock method. All outstanding convertible notes, if any, are considered common stock at the beginning of the period or at the time of issuance, if later, pursuant to the if-converted method. Since the effect of common stock equivalents is anti-dilutive with respect to losses, the stock options and warrants have been excluded from the Company’s computation of net loss per common share for the years ended December 31, 2024 and 2023.

F-16

The following table summarizes the securities that would be excluded from the diluted per share calculation because the effect of including these potential shares was antidilutive due to the Company’s net loss position even though the exercise price could be less than the most recent fair value of the common shares:

Schedule of anti-dilutive shares |  |  |  |  |  |  |  |
|  | Years Ended December 31, |
|  | 2024 |  |  | 2023 |
Warrants |  |  | 2,662,250 |  |  |  | 2,662,250 |
Options |  |  | 3,071,635 |  |  |  | 2,281,879 |
Total |  |  | 5,733,885 |  |  |  | 4,944,129 |

Stock-Based Compensation

The Company applies the provisions of ASC 718, Compensation — Stock Compensation (“ASC 718”), which requires the measurement and recognition of compensation expense for all stock-based awards made to employees, including employee stock options, in the statements of operations and comprehensive loss.

For stock options issued to employees and members of the board of directors for their services, the Company estimates the grant date fair value of each option using the Black-Scholes option pricing model. The use of the Black-Scholes option pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the common stock consistent with the expected life of the option, risk-free interest rates and expected dividend yields of the common stock. For awards subject to service-based vesting conditions, including those with a graded vesting schedule, the Company recognizes stock-based compensation expense equal to the grant date fair value of stock options on a straight-line basis over the requisite service period, which is generally the vesting term. Forfeitures are recorded as they are incurred as opposed to being estimated at the time of grant and revised.

Pursuant to ASU 2018-07 Compensation — Stock Compensation (Topic 718): Improvements to Non-employee Share-Based Payment Accounting, the Company accounts for stock options and restricted shares issued to non-employees for their services in accordance with ASC 718. The Company uses valuation methods and assumptions to value the stock options that are in line with the process for valuing employee stock options noted above.

Warrant Accounting

The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates all its financial instruments, including issued private and public warrants, to determine if such instruments are derivatives or contain features that qualify as embedded derivatives, pursuant to ASC Topic 480, Distinguishing Liabilities from Equity, and ASC Topic 815-40, Derivatives and Hedging: Contracts in Entity’s Own Equity (“ASC 815-40”). The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is assessed as part of this evaluation. During the reporting periods the public warrants were outstanding, they were precluded from liability classification, being equity-classified.

Research and Development

Research and development costs are charged to operations as incurred. For the years ended December 31, 2024 and 2023, the Company recorded approximately $1,191,000 1,190,884 and $1,922,000, 1,921,811 respectively.

F-17

Equity Method Investments

The company accounts for its investments in common stock or in-substance common stock that give it the ability to exercise significant influence over as an equity method investment in accordance with the guidance in ASC 323, Equity Method and Joint Ventures. Specifically, the company initially recognizes its investment in investees as an asset at cost. Further, the company subsequently measures its investment by recognizing its share of earnings or losses of the investee in the period in which they are reported.

Segment Information

Operating segments are defined as components of an enterprise for which separate discrete information is available for evaluation by the chief operating decision maker or decision-making group in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business as one operating and reporting segment, which is the business of designing and developing innovative neurostimulation products.

Recent Accounting Pronouncements

In August of 2023, the FASB issued ASU 2023-05, Business Combinations—Joint Venture (“JV”) Formations: Recognition and Initial Measurement. The guidance requires newly formed JVs to apply a new basis of accounting to all of its contributed net assets, which results in the JV initially measuring its contributed net assets under ASC 805-20, Business Combinations. The new guidance would be applied prospectively and is effective for all newly formed joint venture entities with a formation date on or after January 1, 2025, with early adoption permitted. The Company is evaluating the accounting and disclosure requirements of this update and does not expect them to have a material effect on the consolidated financial statements.

In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The ASU expands public entities’ segment disclosures by requiring disclosure of significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segment’s profit or loss and assets. All disclosure requirements under ASU 2023-07 are also required for public entities with a single reportable segment. The ASU is effective on a retrospective basis for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The Company adopted this update effective December 31, 2024, on a retrospective basis. Refer to Note 11 for the disclosures related to our single operating segment.

In December of 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, establishes incremental disaggregation of income tax disclosures pertaining to the effective tax rate reconciliation and income taxes paid. This standard is effective for fiscal years beginning after December 15, 2024, and requires prospective application with the option to apply it retrospectively. Early adoption is permitted. The Company is currently evaluating the potential impact of adopting this standard on our disclosures.

In November 2024, the FASB issued ASU 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. This ASU requires additional disaggregated disclosures in the notes to financial statements for certain categories of expenses that are included on the face of the income statement. The standard is effective for fiscal years beginning after December 15, 2026 and for interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the effect of adopting this guidance on its consolidated financial statements.

All other newly issued but not yet effective accounting pronouncements have been deemed to be not applicable or immaterial to the Company.

F-18

NOTE 4 — ACCRUED EXPENSES

Accrued expenses consist of the following amounts:

Schedule of accrued expenses |  |  |  |  |  |  |  |
|  | December 31, 2024 |  |  | December 31, 2023 |
Accrued – other |  | $ | 61,415 |  |  | $ | 21,954 |
Accrued settlement liabilities |  |  | 89,330 |  |  |  | 89,330 |
Accrued bonuses – related party |  |  | 240,000 |  |  |  | 150,000 |
Total |  | $ | 390,745 |  |  | $ | 261,284 |

NOTE 5 — NON-CONSOLIDATED JOINT VENTURE AND RELATED PARTY TRANSACTIONS

Formalization of Joint Venture

On May 31, 2023, the Company formalized an agreement related to the formation of a joint venture (the “Joint Venture”) established to engage in the clinical development, marketing, sale and distribution of Nexalin’s second generation transcranial Alternating Current Stimulation (“tACS”) devices (“Gen-2 devices”) in China and other countries in the region. The Joint Venture is registered in Hong Kong.

As of the date of this Report, (i) we have no employees or office in China and none of our operations are conducted in China; and (ii) the Joint Venture does not maintain any variable interest entity structure or operate any data center in China.

Under the Joint Venture Agreement, Wider is obligated to fund all operations for the initial 12-month period of the Joint Venture, after which Nexalin and Wider plan to jointly fund the Joint Venture’s operating expenses in accordance with their pro rata ownership.

The Joint Venture is controlled by a Board of Directors in which Wider is to have sole representation but neither the Company nor Wider has exclusive decision-making ability over day-to-day or significant operational decisions. Wider and Nexalin own 52% and 48% of the Joint Venture, respectively. In accordance with ASC 323 and ASC 810, the Company recognized $4,851 and $0 for the years ended December 31, 2024 and 2023, respectively, on the consolidated statements of operations and comprehensive loss.

The investment in the Joint Venture is accounted for using the equity method of accounting. As of December 31, 2024 and 2023 the Company had an Equity Method Investment of $864 and $100,651, respectively, recorded on the consolidated balance sheets. The Company invested $96,000 in the joint venture in September 2023 and Wider invested $104,000. In accordance with ASC 323, the Company uses the equity method of accounting for its investment in the Joint Venture, an unconsolidated entity over which it does not have a controlling interest. The equity method of accounting requires the investment to be initially recorded at cost and subsequently adjusted for the Company’s share of equity in the unconsolidated entity’s earnings or losses. The Company evaluates the carrying amount of this investment in the Joint Venture for impairment in accordance with ASC 323. If the Company determines that a loss in the value of the investment is other than temporary, the Company writes down the investment to its estimated fair value. Any such losses are recorded to equity in income of unconsolidated entities in the Company’s consolidated statements of operations and comprehensive loss. The Company has made an election to classify distributions received from the Joint Venture using the nature of the distribution approach. Distributions received are classified as cash inflows from operating activities based on the nature of the activities of the unconsolidated entity.

F-19

Under the preceding terms of the collaborative arrangement between the Company and Wider, Wider served as an authorized distributor of the Company’s Gen-2 devices in Asia. As part of the consideration for Wider’s performance of its obligations to the Company prior to the recent formalization of the Joint Venture, the Company and certain designated Wider shareholders entered into stock issuance agreements for the issuance of 450,000 shares of the Company’s common stock, and simultaneously with the execution of this service agreement, Wider invested $200,000 to the Company. During the year ended December 31, 2020, the Company issued 150,000 shares to affiliates of Wider in satisfaction of the obligation. Under the terms of the collaborative agreement, designated shareholders of Wider are entitled to an additional 300,000 shares upon Wider’s achievement of certain milestones. The fair value of the 150,000 shares issued during the year ended December 31, 2020 (less the invested $200,000 in cash) resulted in a charge to stock-based compensation of $550,000 and was recorded in selling, general and administrative expenses on the consolidated statement of operations and comprehensive loss. During the twelve months ended December 31, 2023, the Company issued an additional 150,000 shares to affiliates of Wider in satisfaction of obligations pursuant to the collaborative agreement and also recognized its obligation to issue an additional 150,000 shares. The grant date fair value of the 300,000 shares issued and to be issued resulted in a charge to research and development of $1,500,000 and was recorded in selling, general and administrative expenses on the consolidated statement of operations and comprehensive loss. During the twelve months ended December 31, 2024, the Company issued 331,818 shares of common stock to Wider and affiliates of Wider, in satisfaction of obligations pursuant to their collaborative agreement and their continuing research and development efforts. A charge to research and development was recorded in 2023 at the time the Company recognized its obligation to issue the shares pursuant to the collaborative agreement. A charge to research and development was recorded in 2024 for the continuing research and development efforts.

U.S. Asian Consulting Group, LLC

On May 9, 2018, the Company entered into a five-year consulting agreement with U.S. Asian Consulting Group, LLC (“U.S. Asian”). The consulting agreement was extended for an additional period of eight years upon the closing of our initial public offering. The agreement was amended effective as of July 1, 2024 to expand the services. The two members of U.S. Asian are shareholders in the Company, including Marilyn Elson who is Nexalin’s Controller.

Pursuant to the consulting agreement, U.S. Asian provides consulting services to the Company with regard to, among other things, corporate development, financing arrangements and international operations. The Company was paying U.S. Asian $10,000 per month for services rendered pursuant to the consulting agreement. The amended agreement calls for a monthly fee of $16,667, a onetime stock grant and a semi-annual share award equal to $100,000 with the issuance and delivery of shares to take place following the termination of the consulting agreement. The Company recorded consulting expenses related to the consulting agreement of $160,002 and stock compensation expense of $196,000 for the year ended December 31, 2024 and $120,000 of consulting expenses and stock compensation expense of $0 for the year ended December 31, 2023, respectively.

In 2024 Leonard Osser was issued 200,000 shares of Company stock as compensation for his 2024 services on the Advisory Board. The Company recorded $196,000 and $0 of stock compensation expense for the years ended December 31, 2024 and 2023 respectively.

Officers

On July 1, 2023, the Company entered into a new employment agreement with Mark White to serve as Chief Executive Officer, a new services agreement with David Owens, M.D. to serve as Chief Medical Officer and a new employment agreement with Michael Nketiah to serve as Senior Vice President, Quality, Regulatory and Clinical Affairs. Each of the foregoing agreements are governed by three-year terms and provide compensation in the form of performance-and service-based stock option awards based on the closing price of the Company’s publicly traded common stock on the applicable date of grant. On July 29, 2024, Michael Nketiah submitted his resignation effective August 16, 2024.

Effective September 16, 2024, the Company entered into an agreement with Ms. Carolyn Shelton to serve as Senior Vice President, Quality, Regulatory and Clinical Affairs.

Under the terms of his employment agreement, Mr. White is entitled to (i) a sign-on/retention bonus consisting of a one-time lump-sum payment of $50,000 and a grant of nonqualified stock options to purchase 1,387,024 shares of the Company’s common stock with an exercise price of $.894 per share subject to certain time and performance-based vesting conditions.

F-20

Under the terms of his service agreement, Dr. Owens is entitled to (i) a sign-on/retention bonus consisting of a grant of nonqualified stock options to purchase 654,362 shares of the Company’s common stock with an exercise price of $.894 per share subject to certain time and performance-based vesting conditions. The 2023 performance-based milestones regarding Dr. Owen’s incentive compensation have been met for 2023, and he was awarded 271,454 nonqualified stock options with a vesting date of July 1, 2024. The 2024 performance-based milestones regarding Dr. Owen’s incentive compensation have been met for 2024, and he was awarded 271,454 nonqualified stock options with a vesting date of July 1, 2025. Dr. Owens was awarded an additional 125,000 vested options exercisable at $2.95.

Under the terms of his employment agreement Mr. Nketiah was entitled to nonqualified stock option grants to purchase 100,671 shares of the Company’s common stock with an exercise price of $.894 subject to certain time and performance-based vesting conditions.

Under the terms of her agreement Ms. Shelton is entitled to nonqualified stock option grants to purchase 90,620 shares of the Company’s common stock with an exercise price of $.6621, subject to certain time and performance-based vesting conditions.

In addition to the retention payments, stock awards and nonqualified option grants described above, Messrs. White and Nketiah are receiving cash compensation and each of Messrs. White and Nketiah are eligible for performance-based cash bonuses. The 2023 performance-based milestones regarding Mr. White’s incentive compensation have been met for 2023, and he was awarded a cash bonus of $120,000 and 313,199 nonqualified stock options with a vesting date of July 1, 2024. The 2024 performance-based milestones regarding Mr. White’s incentive compensation have been met for 2024, and he was awarded a cash bonus of $220,000 and 313,199 nonqualified stock options with a vesting date of July 1, 2025. The 2023 performance-based milestones regarding Mr. Nketiah’s incentive compensation were met for 2023, and he was awarded a cash bonus of $50,000 and 33,557 nonqualified stock options with a vesting date of July 1, 2024.

The reported amounts are calculated in accordance with the provisions of Financial Accounting Standards Board (“FASB”) Accounting Standard Codification Topic 718, “Compensation — Stock Compensation (“ASC 718”). ASC 718 focuses primarily on accounting for transactions in which an entity obtains employee services in share-based payment transactions, such as the options issued under our 2023 Plan.

Leases

Our principal executive office is located at 1776 Yorktown, Suite 550, Houston, Texas 77056. Under ASC 842 “Leases”, we have two separate sub-leases (through IIcom Strategic Inc. controlled and owned by our Chief Executive Officer) totaling approximately 4,000 square feet of office space under operating leases. Management and supporting staff are hosted at this location. Our lease costs for each of the twelve months ended December 31, 2024 and 2023 were $54,000. The initial sub-leases expired in January of 2024. The Company has entered into a new one year sublease for 4,000 square feet of office space under a short term lease. Pursuant to the sublease, the Company pays and will pay the third party landlord (not the sub landlord) all direct and indirect rent costs under the primary lease directly for the leased premises. No additional payments are made to the Chief Executive Officer or the entity controlled by him.

NOTE 6 — LOANS PAYABLE

Legacy Ventures International, Inc.

On December 11, 2017, the Company issued a promissory note (the “Promissory Note”) in favor of Legacy Ventures International, Inc. (“Legacy”) as part of a commercial transaction with Legacy that was never consummated. The Promissory Note was issued in the original principal amount of $500,000, with interest at 4% per annum and a maturity date of December 31, 2017. As of December 31, 2022, this promissory note was in default. The Company recorded $20,000 of interest expense in the year ended December 31, 2023. The amount outstanding at December 31, 2023 was $0. The Company evaluated ASC 405-20, Extinguishments of Liabilities (“ASC 405-20”). Pursuant to ASC 405-20, a liability has been extinguished if either of the following conditions is met (a) the debtor pays the creditor and is relieved of its obligation for the liability and (b) the debtor is legally released from being the primary obligor under the liability, either judicially or by the creditor. In consultation with its legal counsel, the Company determined that the second condition was met by virtue of the expiration of the applicable statute of limitations. As such, Promissory Note was accounted for as a debt extinguishment. As part of the debt extinguishment the Company wrote off the $500,000 principal amount and accrued interest of $115,000 at December 31, 2023.

F-21

NOTE 7 — STOCKHOLDERS’ EQUITY

Issuance of Common Stock

During the year ended December 31, 2024, the Company issued an aggregate of 5,866,961 shares of its common stock, as follows:

| ● | 150,000 shares of common stock were issued to affiliates of Wider in satisfaction of obligations pursuant to their collaborative agreement. A charge to research and development of $750,000 was recorded in 2023 at the time the Company recognized its obligation to issue these shares.

| ● | 181,818 shares of common stock were issued to Wider in consideration of Wider’s research and development efforts for which a charge to research and development of $400,000 was recorded in 2024.

| ● | 3,000,000 shares of common stock were issued to investors for net proceeds of $4,516,184.

| ● | 2,535,143 shares of common stock were issued for services in lieu of cash of which 1,492,457 were issued to outside consultants, 200,000 to a related party, 542,500 to certain employees of the Company, and 300,186 to current and former members of the Board of Directors for their services as Board Members.

During the year ended December 31, 2023, the Company issued 150,000 shares to certain designated Wider stockholders pursuant to the terms of the collaborative agreement between the Company and Wider. The amount expensed during the year ended December 31, 2023 in the audited consolidated statement of operations and comprehensive loss was $1,500,000 which included the value of 150,000 of additional shares not yet issued.

On December 12, 2023, various consultants, Board members and employees were awarded shares of common stock and/or stock options with a value of $642,029. The December 12, 2023 awards are subject to shareholder approval to amend our 2023 Equity Incentive Plan so as to provide for additional shares to be available for the grant of awards. The amount expensed during the year ended December 31, 2023 in the audited consolidated statement of operations and comprehensive loss was related to the December 12, 2023 awards was $642,029.

Options

Nexalin’s 2023 Equity Incentive Plan (the “2023 Plan”) was approved by our stockholders on November 10, 2023, and an amendment to the 2023 Plan was approved by our stockholders on August 26, 2024, to provide for additional shares to be available for the grant of awards. The Plan provides that maximum number of shares of common stock available for the grant of awards under the Plan shall be 6,000,000, subject to adjustment for stock dividends, stock splits or similar events. The 2023 Plan is administered by the Compensation Committee of the Board of Directors, which may in turn delegate administrative authority to one or more of our executive officers. Under the terms of the 2023 Plan, the Compensation Committee may grant equity awards, including nonqualified stock options and restricted stock to employees, officers, directors, consultants, agents, advisors and independent contractors.

On July 1, 2023, the company entered into amended employment agreements with the three executives. In addition to the cash compensation included in their employment contracts, the three executives were granted one-time bonus stock options (that were immediately vested) and performance-based stock options that would be triggered based on certain performance criteria being achieved. The amount expensed during the year ended December 31, 2024 and December 31, 2023 in the audited consolidated statement of operations and comprehensive loss was $774,277 and $271,342, respectively.

F-22

The following table presents a summary of stock option award activity during the year ended December 31, 2024:

Schedule of stock option award activity |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  | Number of options |  |  | Weighted Average Exercise Price |  |  | Weighted Average Remaining Life |  |  | Aggregate Intrinsic Value |
Outstanding December 31, 2023 |  |  | 2,281,879 |  |  | $ | 0.89 |  |  |  | 9.50 |  |  | $ | - |
Issued |  |  | 856,870 |  |  |  | 1.34 |  |  |  | 4.23 |  |  |  | 1,247,987 |
Exercised |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
Expired or cancelled |  |  | (67,114 | ) |  |  | 0.89 |  |  |  | 3.50 |  |  |  | - |
Outstanding December 31, 2024 |  |  | 3,071,635 |  |  | $ | 1.02 |  |  |  | 7.26 |  |  | $ | 5,380,738 |

The following table provides additional information about stock options that are outstanding and exercisable at December 31, 2024:

| Schedule of additional information about stock options |  |  |  |  |  |  |  |  |  |  |  |  |
Exercise Price |  |  | Outstanding Number of Options |  |  | Weighted Average Remaining Life In Years |  |  | Exercisable Number of Options |
$ | 0.89 |  |  |  | 2,214,765 |  |  | $ | 8.50 |  |  |  | 1,152,125 |
| 0.94 |  |  |  | 581,250 |  |  |  | 4.00 |  |  |  | 581,250 |
| 0.66 |  |  |  | 90,620 |  |  |  | 4.17 |  |  |  | - |
| 2.95 |  |  |  | 185,000 |  |  |  | 5.00 |  |  |  | 125,000 |
|  |  |  |  | 3,071,635 |  |  | $ | 7.26 |  |  |  | 1,858,375 |

The fair value of these stock option awards is estimated as of the grant date using a Black-Scholes option pricing model and the following assumptions: A risk-free interest rate based on the U.S. Treasury yield curve at the date of grant; an expected or contractual term; and expected volatility based on an evaluation of comparable public companies’ measures of volatility. The Company does not anticipate declaring dividends on common shares now or in the near future and has therefore assumed no dividend rate. The following table discloses the assumptions utilized for stock options awarded during each year as follows:

Schedule of assumptions |  |  |  |  |  |  |  |
|  | December 31, 2024 |  |  | December 31, 2023 |
Volatility |  |  | 103.8-129.2 | % |  |  | 99.0 | %
Expected dividends |  | $ | - |  |  | $ | - |
Risk-free interest rate |  |  | 3.66-4.45 | % |  |  | 4.61 | %
Expected term (years) |  |  | 5-10 |  |  |  | 9.5 |

Warrants

F-23

The issuance of warrants to purchase shares of the Company’s common stock are summarized as follows:

Schedule of warrants |  |  |  |  |  |  |  |
|  | Number of Warrants |  |  | Weighted Average Exercise Price |
Outstanding December 31, 2023 |  |  | 2,662,250 |  |  | $ | 4.15 |
Issued |  |  | - |  |  |  | - |
Exercised |  |  | - |  |  |  | - |
Expired or cancelled |  |  | - |  |  |  | - |
Outstanding December 31, 2024 |  |  | 2,662,250 |  |  | $ | 4.15 |

The following table summarizes information about warrants to purchase shares of the Company’s common stock outstanding and exercisable at December 31, 2024:

| Summary information about warrants to purchase |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Exercise Price |  |  | Outstanding Number of Warrants |  |  | Weighted Average Remaining Life In Years |  |  | Weighted Average Exercise Price |  |  | Exercisable Number of Warrants |
$ | 4.15 |  |  |  | 2,662,250 |  |  |  | 0.75 |  |  | $ | 4.15 |  |  |  | 2,662,250 |

The compensation expense attributed to the issuance of the warrants, if required to be recognized on the nature of the transaction, was recognized as they vested/earned. These warrants are exercisable up to three years from the date of grant. All are currently exercisable.

NOTE 8 — COMMITMENTS AND CONTINGENCIES

Legal Claims

There are no material pending legal proceedings in which the Company or any of its subsidiaries is a party or in which any director, officer or affiliate of the Company, any owner of record or beneficially of more than 5% of any class of its voting securities, or security holder is a party adverse to us or has a material interest adverse to the Company other than the following:

Sarah Veltz v. Nexalin Technology, Inc. et al.

Plaintiff, Sarah Veltz, filed a lawsuit in this matter on January 20, 2021 in Orange County Superior Court (Case No. 30-2021-01180164-CU-WT-CJC) (the “Complaint”) naming the Company and others as defendants. In her Complaint, Plaintiff contends that she was employed by defendants, including Nexalin, and has not been paid all wages, including overtime wages and other benefits allegedly due her. Plaintiff also contends that, during her employment, she was subjected to sexual harassment by the Company’s then Chief Executive Officer. Plaintiff seeks both compensatory and punitive damages. On March 12, 2021, the Company filed its answer to the Complaint. A Mediation was held on March 5, 2025. A settlement has not yet been reached. The court has set a trial in this matter for June 9, 2025. Management’s intent is to contest the allegations vigorously and, as of the date of this Report, is unable to provide an evaluation of the potential outcome of the litigation within the probable or remote range or to provide an estimate of the amount of or a range of potential loss that might be incurred by the Company.

F-24

Employment Development Department

The Company is currently engaged in settlement discussions with the Employment Development Department (EDD) of the State of California. This matter involves issues related to our previous management’s classification of certain work provided to or on behalf of the Company’s business as contract labor instead of employee labor. The total amount involved was approximately $300,000. Management has petitioned for reassessment and believes the hired workers at issue were indeed actual contractors and not employees. We have no business in California other than one part time and one full time worker residing in California. The EDD approved a significant downward adjustment in our outstanding employment tax liability to approximately $40,000 as reflected on its Statement of Account dated November 30, 2023. We are in negotiations with the EDD and have presented a settlement offer. The Company has accrued $40,000 and $40,000 on the consolidated balance sheets as of December 31, 2024 and December 31, 2023, respectively. The reduction in the amount accrued was recognized as other income on the consolidated statement of operations and comprehensive loss during the year ended December 31, 2023. The Company believes it has adequately accrued for this matter.

Demand Letter from The University of Arizona

On December 8, 2022, the Company received a demand letter from the University of Arizona seeking payment of $111,094 The Company and the University of Arizona agreed on the terms of a settlement for the amounts claimed by the University, whereby the Company will pay an aggregate of approximately $69,000 (in three equal monthly payments) in full satisfaction of amounts the University claims it is owed. The settlement amount was paid in full as of December 31, 2023.

NOTE 9 — CONCENTRATION OF CREDIT RISK

Revenues

Two customers accounted for 58% of revenues for the year ended December 31, 2024 as set forth below:

Concentration of credit risk |  |  |  |
Customer A |  |  | 47 | %
Customer B |  |  | 11 | %

Three customers accounted for 62% of revenues for the year ended December 31, 2023 as set forth below:

Customer A |  |  | 25 | %
Customer B |  |  | 19 | %
Customer C |  |  | 18 | %

Accounts Receivable

Three customers accounted for 88% of accounts receivable at December 31, 2024.

Customer A |  |  | 50 | %
Customer B – related party |  |  | 23 | %
Customer C |  |  | 15 | %

Five customers accounted for 96% of accounts receivable at December 31, 2023.

Customer A – related party |  |  | 39 | %
Customer B |  |  | 21 | %
Customer C |  |  | 15 | %
Customer D |  |  | 12 | %
Customer E |  |  | 10 | %

F-25

NOTE 10 — INCOME TAXES

The Company identified their federal and Texas state tax returns as their “major” tax jurisdictions. The periods for income tax returns that are subject to examination for these jurisdictions is 2019 through 2024. The Company believes their income tax filing positions and deductions would be sustained on audit, and they do not anticipate any adjustments that would result in a material change to their financial position. Therefore, no liabilities for uncertain tax positions have been recorded.

As of December 31, 2024, the Company had approximately $23.8 million in net operating loss carry-forwards for federal and state income tax reporting (not tax effected) purposes. As a result of the Tax Cuts Job Act 2017 (the “Act”), certain future carryforwards do not expire. The Company has not performed a formal analysis but believes its ability to use such net operating losses and tax credit carryforwards in the future is subject to annual limitations due to change of control provisions under Sections 382 and 383 of the Internal Revenue Code, which will significantly impact its ability to realize these deferred tax assets.

The Company’s net deferred tax assets, liabilities and valuation allowance as of December 31, 2024 and 2023 are summarized as follows:

Deferred tax assets, liabilities |  |  |  |  |  |  |  |
|  | Year Ended December 31, |
|  | 2024 |  |  | 2023 |
Deferred tax assets: |  |  |  |  |  |  |  |
Net operating loss carryforwards |  | $ | 4,999,000 |  |  | $ | 3,504,000 |
R&D costs |  |  | 376,000 |  |  |  | 200,000 |
Accrued bonus |  |  | 50,000 |  |  |  | - |
Stock-based compensation |  |  | 323,000 |  |  |  | 215,000 |
Total deferred tax assets |  |  | 5,748,000 |  |  |  | 3,919,000 |
Valuation allowance |  |  | (5,748,000 | ) |  |  | (3,919,000 | )
Net deferred tax assets |  | $ | - |  |  | $ | - |

We recorded a valuation allowance in the full amount of our net deferred tax assets since realization of such tax benefits has been determined by our management to be less likely than not. The valuation allowance increased by approximately $1,830,000 and $543,000 during the years ended December 31, 2024 and 2023, respectively.

A reconciliation of the statutory federal income tax benefit to actual tax benefit for the years ended December 31, 2024 and 2023 is as follows:

Schedule of effective income tax rate reconciliation |  |  |  |  |  |  |  |
|  | 2024 |  |  | 2023 |
Federal statutory blended income tax rates |  |  | (21 | )% |  |  | (21 | )%
State statutory income tax rate, net of federal benefit |  |  | (- | ) |  |  | (- | )
Non-deductible R&D costs |  |  | - |  |  |  | 6 |
Permanent differences |  |  | (3 | ) |  |  | 2 |
Change in valuation allowance |  |  | 24 |  |  |  | 12 |
Other |  |  | - |  |  |  | 1 |
Effective tax rate |  |  | - | % |  |  | - | %

F-26

NOTE 11 — SEGMENT INFORMATION

The Company views its operations and manages its business as one operating and reportable segment, which is the business of designing and developing innovative neurostimulation products. The Company’s focus centers around the treatment of various mental health conditions without the need for drugs or psychotherapy. Consistent with the operational structure, the Chief Executive Officer, as the chief operating decision maker (“CODM”), manages and allocates resources on a consolidated basis. This decision-making process reflects the way in which the financial information is regularly reviewed and used by the CODM to evaluate performance, set operational targets, forecast future financial results, and allocate resources.

The Company’s CODM assesses financial performance and allocates resources based on consolidated net loss that also is reported on the consolidated statements of operations and comprehensive loss. The measure of segment assets is reported on the consolidated balance sheets as total consolidated assets. The CODM utilizes consolidated net loss by comparing actual results against budgeted amounts on a quarterly basis. As part of this process, consolidated net loss is a critical performance measure used to evaluate the Company’s operating performance and guide strategic decisions and resource allocations, including additional investments in research and development and commercialization activities.

The following table provides information about the Company’s one reportable segment and includes the reconciliation to consolidated net loss.

Schedule of segment reporting information |  |  |  |  |  |  |  |
|  | Year ended December 31, |
|  | 2024 |  |  | 2023 |
Total revenues(b) |  | $ | 168,721 |  |  | $ | 110,748 |
Less: |  |  |  |  |  |  |  |
Cost of revenues |  |  | 36,593 |  |  |  | 25,688 |
Research and development expense (excluding stock-based compensation expense): |  |  |  |  |  |  |  |
Clinical trials |  |  | 87,492 |  |  |  | 80,569 |
HALO Design |  |  | 534,527 |  |  |  | 336,870 |
SYNC project |  |  | 102,565 |  |  |  | - |
Other research and development(a) |  |  | 66,300 |  |  |  | 4,372 |
General and administrative expense (excluding share-based compensation expense) |  |  | 2,553,459 |  |  |  | 2,367,821 |
Amortization |  |  | 15,107 |  |  |  | 3,751 |
Stock-based compensation expense |  |  | 3,560,509 |  |  |  | 2,413,375 |
Professional fees |  |  | 966,815 |  |  |  | 574,598 |
Interest (income) expense, net |  |  | (3,193 | ) |  |  | 38,835 |
Equity in net income from equity method investees |  |  | (4,851 | ) |  |  | - |
Other income |  |  | (139,420 | ) |  |  | (1,086,422 | )
Segment net loss |  |  | (7,607,182 | ) |  |  | (4,648,709 | )
Reconciliation of net loss |  |  |  |  |  |  |  |
Adjustments and reconciling items |  |  | - |  |  |  | - |
Consolidated net loss |  | $ | (7,607,182 | ) |  | $ | (4,648,709 | )

(a) | Other research and development expenses primarily consist of facilities charges, third party consultant costs, costs related to other product candidates, and other unallocated costs.
(b) | Revenue concentrations are reflected in Note 9

F-27